Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Jumpei Teramachi, DDS, PhD, Masahiro Hiasa, PhD DDS, Asuka Oda, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Takeshi Harada, MDPhD, Derek Hanson, Keiichiro Watanabe, DDS, PhD, Shiro Fujii, MD, Kumiko Kagawa, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Itsuro Endo, MD PhD, Shuji Ozaki, MD PhD, Toshio Matsumoto, MD PhD, Masahiro Abe, MD PhD

Blood (2015) 126 (23): 4203.

https://doi.org/10.1182/blood.V126.23.4203.4203

Published: 2015

Journal Articles

Targeting Myeloma Cells and Their Progenitors By Pim Kinase Inhibition

Shiro Fujii, MD, Hirokazu Miki, MD PhD, Asuka Oda, PhD, Keiichiro Watanabe, DDS, Ryota Amachi, DDS, Hikaru Yagi, MD, Kimiko Sogabe, MD, Mamiko Takahashi, MD, Tomoko Maruhashi, MD, Kengo Udaka, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, Toshio Matsumoto, MD PhD, Masahiro Abe

Blood (2014) 124 (21): 5724.

https://doi.org/10.1182/blood.V124.21.5724.5724

Published: 2014

Journal Articles

Robust Induction Of Th1-Like γδ T Cells With Anti-Myeloma Activity By Lenalidomide In Combination With HMB-PP As Well As Zoledronic Acid

Takeshi Harada, MD, Qu Cui, MD, PhD, Shingen Nakamura, MD, PhD, Hirokazu Miki, MD, PhD, Asuka Oda, PhD, Ryota Amachi, DDS, Masami Iwasa, MD, Kengo Udaka, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, PhD, Shuji Ozaki, MD, PhD, Yoshimasa Tanaka, MD, PhD, Toshio Matsumoto, MD, PhD, Masahiro Abe, MD, PhD

Blood (2013) 122 (21): 129.

https://doi.org/10.1182/blood.V122.21.129.129

Published: 2013

Journal Articles

Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition

Shiro Fujii, MD, Masami Iwasa, MD, Takeshi Harada, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, PhD, Ryota Amachi, DDS, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Shuji Ozaki, MD, PhD, Toshio Matsumoto, MD, PhD, Masahiro Abe, MD, PhD

Blood (2012) 120 (21): 5011.

https://doi.org/10.1182/blood.V120.21.5011.5011

Published: 2012

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Hirokazu Miki, MD, Masahiro Abe, MD, PhD, Kumiko Kagawa, MD, Asuka Oda, PhD, Hiroe Amou, PhD, Akishige Ikegame, PhD, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ayako Nakano, MD, PhD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Yukimasa Shiotsu, PhD, Masaki Ri, MD, Shinsuke Iida, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 5104.

https://doi.org/10.1182/blood.V118.21.5104.5104

Published: 2011

Journal Articles

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Ayako Nakano, MD, PhD, Masahiro Abe, MD, PhD, Daisuke Tsuji, PhD, Hirokazu Miki, MD, Akishige Ikegame, PhD, Shingen Nakamura, MD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Kohji Itoh, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 135.

https://doi.org/10.1182/blood.V118.21.135.135

Published: 2011

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Hiroe Amou, PhD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 1833.

https://doi.org/10.1182/blood.V118.21.1833.1833

Published: 2011

Journal Articles

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Keiichiro Watanabe, DDS, Masahiro Abe, MD, PhD, Qu Cui, MD, Makoto Kawatani, PhD, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Tadashi Jinno, MD, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Eiji Tanaka, DDS, PhD, Hiroyuki Osada, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 454.

https://doi.org/10.1182/blood.V116.21.454.454

Published: 2010

Journal Articles

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Qu Cui, MD, Masahiro Abe, MD, PhD, Hirokazu Miki, MD, Shingen Nakamura, MD, Keiichiro Watanabe, DDS, Akishige Ikegame, Masahiro Hiasa, DDS, PhD, Ayako Nakano, MD, PhD, Takeshi Harada, MD, Shiro Fujii, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2010) 116 (21): 3025.

https://doi.org/10.1182/blood.V116.21.3025.3025

Published: 2010

Journal Articles

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

Shingen Nakamura, Masahiro Abe, Qu Cui, Ayako Nakano, Asuka Oda, Hiroe Amou, Akishige Ikegame, Takeshi Harada, Masahiro Hiasa, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Shuji Ozaki, Toshio Matsumoto

Blood (2009) 114 (22): 1823.

https://doi.org/10.1182/blood.V114.22.1823.1823

Published: 2009

Journal Articles

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma.

Akishige Ikegame, Shuji Ozaki, Daisuke Tsuji, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Masahiro Abe, Kohji Itoh, Toshio Matsumoto

Blood (2009) 114 (22): 2799.

https://doi.org/10.1182/blood.V114.22.2799.2799

Published: 2009

Journal Articles

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Masahiro Hiasa, Masahiro Abe, Ayako Nakano, Asuka Oda, Hiroe Amou, Shinsuke Kido, Kyoko Takeuchi, Kumiko Kagawa, Kenichiro Yata, Toshihiro Hashimoto, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka, Keiji Moriyama, Toshio Matsumoto

Blood (2009) 114 (20): 4517–4526.

https://doi.org/10.1182/blood-2009-04-215020

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

Kenichiro Yata, Masahiro Abe, Asuka Oda, Hiroe Amou, Masahiro Hiasa, Kyoko Takeuchi, Shingen Nakamura, Osamu Tanaka, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto

Blood (2008) 112 (11): 1685.

https://doi.org/10.1182/blood.V112.11.1685.1685

Published: 2008

Journal Articles

KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts.

Hirokazu Miki, Shuji Ozaki, Osamu Tanaka, Shingen Nakamura, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Masahiro Abe, Toshio Matsumoto

Blood (2008) 112 (11): 1669.

https://doi.org/10.1182/blood.V112.11.1669.1669

Published: 2008

Journal Articles

Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells.

Ali Jalili, PhD, Shuji Ozaki, MD, Naoki Kimura, PhD, Masahiro Abe, MD, Toshio Matsumoto, MD

Blood (2007) 110 (11): 2376.

https://doi.org/10.1182/blood.V110.11.2376.2376

Published: 2007

Journal Articles

The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.

Jin Asano, MD, Masahiro Abe, MD, Shiro Fujii, MD, Osamu Tanaka, MD, Ai Mihara, MD, Shingen Nakamura, MD, Kazuhiro Miki, MD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Masahiro Hiasa, DDS, Toshio Matsumoto, MD

Blood (2007) 110 (11): 243.

https://doi.org/10.1182/blood.V110.11.243.243

Published: 2007

Journal Articles

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.

Kumiko Kagawa, MD, Masahiro Abe, MD, Shiro Fujii, MD, Osamu Tanaka, MD, Ai Mihara, MD, Shingen Nakamura, MD, Kazuhiro Miki, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Masahiro Hiasa, DDS, Toshio Matsumoto, MD

Blood (2007) 110 (11): 244.

https://doi.org/10.1182/blood.V110.11.244.244

Published: 2007

Journal Articles

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

Hirokazu Miki, MD, Shuji Ozaki, MD, Osamu Tanaka, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ai Mihara, MD, Kumiko Kagawa, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Kenichiro Yata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Toshio Matsumoto, MD

Blood (2007) 110 (11): 4783.

https://doi.org/10.1182/blood.V110.11.4783.4783

Published: 2007

Journal Articles

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Kyoko Takeuchi, MD, Masahiro Abe, MD, Asuka Oda, MT, Hiroe Amou, MT, Masahiro Hiasa, DDS, Jin Asano, MD, Kenichi Kitazoe, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, PhD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2006) 108 (11): 3479.

https://doi.org/10.1182/blood.V108.11.3479.3479

Published: 2006

NARROW

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Targeting Myeloma Cells and Their Progenitors By Pim Kinase Inhibition

Robust Induction Of Th1-Like γδ T Cells With Anti-Myeloma Activity By Lenalidomide In Combination With HMB-PP As Well As Zoledronic Acid

Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Inhibition of Hexokinase II Inactivates ABC Transporters and Restores Drug Sensitivity in Myeloma Cells

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

An Acidic Milieu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent

Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

A Recombinant HLA Class I-Specific Single-Chain Fv Diabody Can Target Cancer Stem Cell-Like Side Population Cells in Multiple Myeloma.

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts.

Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells.

The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.

Combination of a Spicamycin Analogue KRN5500 and Chemotherapeutic Agents Synergistically Enhances Their Cytotoxicity in Human Myeloma Cells.

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only